To facilitate diagnosis of critical metabolic markers
QuantRx Biomedical has introduced new point-of-care (POC) diagnostic reader device, Q-Reader, at MEDICA 2009 in Dusseldorf, Germany. The Q-Reader addresses the performing of advanced medical diagnostic procedures where the patient can benefit the most.
In a departure from traditional and simplistic positive/negative testing that has become a billion dollar industry, the Q-Reader for the first time provides quantified information in a POC test, claims the company.
QuantRx has been developing the Q-Reader platform consisting of the Q-Reader and a number of POC tests, intended to facilitate diagnosis of critical metabolic markers, such as those associated with thyroid disease, malignant cancers, therapeutic drugs and other medically relevant conditions, as part of its QN Diagnostics initiative.
The platform technology, which combines the sensitivity of QuantRx’s RapidSense technology with the ultra-portable Q-Reader, enables the use of any biological sample, such as blood, urine, vaginal fluids, or saliva, to deliver laboratory results to the primary care provider.
Walter Witoshkin, chairman and chief executive officer of QuantRx, said: “We were pleased by the interest in the Q-Reader expressed by a number of potential partners. As the world’s largest medical trade fair with almost 138,000 visitors from over 100 countries surpassing last year’s attendance, we were provided with an incredible audience for the milestone of debuting our POC technology.
“Like no other product on the market, our Q-Reader actually defines the level of metabolic markers as a front line tool for point-of-care, rather than necessitating the delayed process of third party clinical laboratory testing. The capabilities and diverse testing applications of the Q-Reader resonated with the healthcare industry constituents are validating our investment in and commitment to this product.”